Allogeneic stem cell transplant for adult Philadelphia chromosome-negative acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 4, 2012, Pages 550-556

  Nishiwaki, Satoshi ^a   Miyamura, Koichi ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

Acute lymphoblastic leukemia; Adolescents and young adults; Allogeneic stem cell transplant; First complete remission; Reduced intensity conditioning

Indexed keywords

ANTINEOPLASTIC AGENT; LEUKOCYTE ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOGENETICS; DONOR; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MINIMAL RESIDUAL DISEASE; MORTALITY; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; UMBILICAL CORD BLOOD; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOID; PHILADELPHIA CHROMOSOME; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84859071896     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.615424     Document Type: Review

References (52)

1. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106:3760-3767.
2. Kantarjian H, Th omas D, O' Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101:2788-2801.
3. Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000;14: 1307 - 1325, ix.
4. Larson RA, Dodge RK, Burns CP, et al. A fi ve-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995;85:2025-2037.
5. Linker C, Damon L, Ries C, et al. Intensifi ed and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002;20:2464-2471.
6. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002;99:863-871.
7. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004;22:4075-4086.
8. Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002;16:1259-1266.
9. Nishiwaki S, Inamoto Y, Imamura M, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with Philadelphia chromosomenegative acute lymphoblastic leukemia in complete remission. Blood 2011;117:3698-3699.
10. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefi t is achieved from a matched sibling allogeneic transplantation in fi rst complete remission, and an autologous transplantation is less eff ective than conventional consolidation/maintenance chemotherapy in all patients: fi nal results of the International ALL Trial (MRC UKALL XII/ ECOG E2993). Blood 2008;111:1827-1833.
11. Marks DI, Perez WS, He W, et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in fi rst complete remission. Blood 2008;112:426-434.
12. Nishiwaki S, Inamoto Y, Sakamaki H, et al. Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but diff erent risk factors between related and unrelated transplantation in fi rst complete remission. Blood 2010;116:4368-4375.
13. Kako S, Morita S, Sakamaki H, et al. A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in fi rst remission who have an HLA-matched sibling donor. Leukemia 2011;25:259-265.
14. Marks DI, Wang T, Perez WS, et al. Th e outcome of full intensity and reduced intensity conditioning matched sibling or unrelated donor (URD) transplantation in adults with Philadelphia chromosome negative acute lymphoblastic leukemia (PH- ALL) in fi rst and second complete remission (CR1 and CR2). Blood 2010;116:366-374.
15. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007;109:3189-3197.
16. Holowiecki J, Krawczyk-Kulis M, Giebel S, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. Th e Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol 2008;142:227-237.
17. Bassan R, Spinelli O, Oldani E, et al. Improved risk classifi cation for risk-specifi c therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009;113:4153-4162.
18. Bruggemann M, Schrauder A, Raff T, et al. Standardized MRD quantifi cation in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010;24:521-535.
19. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010:7-12.
20. Patel B, Rai L, Buck G, et al. Minimal residual disease is a signifi cant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: fi nal results of the international trial UKALL XII/ECOG2993. Br J Haematol 2010;148:80-89.
21. Huguet F, Leguay T, Raff oux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009;27:911-918.
22. Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia eff ect and risk factors determining outcome. Blood 2001;97:1572-1577.
23. Marks DI, Forman SJ, Blume KG, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in fi rst or second complete remission. Biol Blood Marrow Transplant 2006;12:438-453.
24. Oh H, Loberiza FR Jr, Zhang MJ, et al. Comparison of graft-versushost- disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood 2005;105:1408-1416.
25. Baker KS, Loberiza FR Jr, Yu H, et al. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. J Clin Oncol 2005;23:7032-7042.
26. Mehta J. Hematopoietic stem cell transplantation from unrelated donors for acute leukemia. Blood 2008;112:447-448.
27. Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after fi rst relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007;21:1907-1914.
28. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ ECOG 2993 study. Blood 2007;109:944-950.
29. Oriol A, Vives S, Hernandez Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010;95:589-596.
30. Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010;28:3730-3738.
31. Terwey TH, Massenkeil G, Tamm I, et al. Allogeneic SCT in refractory or relapsed adult ALL is eff ective without prior reinduction chemotherapy. Bone Marrow Transplant 2008;42:791-798.
32. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003;21:774-780.
33. Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol 2008;26:1843-1849.
34. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children ' s Cancer Group and Cancer and Leukemia Group B studies. Blood 2008;112:1646-1654.
35. Nachman JB, La MK, Hunger SP, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefi t from intensive postinduction treatment: a report from the children's oncology group. J Clin Oncol 2009;27:5189-5194.
36. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011;29:532-543.
37. Barrett AJ, Savani BN. Stem cell transplantation with reducedintensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006;20:1661-1672.
38. Cho BS, Lee S, Kim YJ, et al. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia 2009;23:1763-1770.
39. Stein AS, Palmer JM, O' Donnell MR, et al. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2009;15:1407-1414.
40. Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010;116:4439-4443.
41. Chessells JM, Hall E, Prentice HG, et al. Th e impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia 1998;12:463-473.
42. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004;351:2265-2275.
43. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004;351:2276-2285.
44. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004;104:3813-3820.
45. Eapen M, Rocha V, Sanz G, et al. Eff ect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010;11: 653-660.
46. Ferra C, Sanz J, de la Camara R, et al. Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source. Biol Blood Marrow Transplant 2010;16:957-966.
47. Tomblyn MB, Arora M, Baker KS, et al. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol 2009;27:3634-3641.
48. Atsuta Y, Suzuki R, Nagamura-Inoue T, et al. Disease-specifi c analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 2009;113:1631-1638.
49. Bachanova V, Verneris MR, DeFor T, et al. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood 2009;113:2902-2905.
50. Sebban C, Lepage E, Vernant JP, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in fi rst complete remission: a comparative study. French Group of Th erapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1994;12:2580-2587.
51. Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004;104:3028-3037.
52. Ribera JM, Oriol A, Bethencourt C, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005;90:1346-1356.